- Home
- MCRI vs KOD Comparison
MCRI vs KOD Comparison
Compare MCRI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | KOD |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MCRI | KOD |
|---|---|---|
| Price | $132.51 | $38.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $111.50 | $35.43 |
| AVG Volume (30 Days) | 187.6K | ★ 826.1K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 41.41 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $395,377,000.00 | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | $87.61 | ★ N/A |
| Revenue Growth | ★ 114.40 | N/A |
| 52 Week Low | $85.66 | $3.72 |
| 52 Week High | $135.93 | $47.84 |
Technical Indicators
Market Signals| Indicator | MCRI | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 69.10 | 58.86 |
| Support Level | $89.37 | $32.93 |
| Resistance Level | N/A | $46.72 |
| Average True Range (ATR) | 3.69 | 2.77 |
| MACD | 0.09 | 0.66 |
| Stochastic Oscillator | 65.73 | 92.72 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.